Share on StockTwits

Tetraphase Pharmaceuticals (NASDAQ:TTPH) CFO David Charles Lubner unloaded 13,530 shares of the company’s stock on the open market in a transaction dated Tuesday, June 17th. The shares were sold at an average price of $12.51, for a total transaction of $169,260.30. Following the transaction, the chief financial officer now directly owns 78,463 shares in the company, valued at approximately $981,572. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) traded up 6.29% during mid-day trading on Wednesday, hitting $12.85. The stock had a trading volume of 195,683 shares. Tetraphase Pharmaceuticals has a 52 week low of $7.02 and a 52 week high of $17.74. The stock’s 50-day moving average is $10.1 and its 200-day moving average is $12.23. The company’s market cap is $331.9 million.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last announced its earnings results on Monday, May 12th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.45) by $0.08. The company had revenue of $2.50 million for the quarter, compared to the consensus estimate of $2.97 million. Analysts expect that Tetraphase Pharmaceuticals will post $-2.07 EPS for the current fiscal year.

TTPH has been the subject of a number of recent research reports. Analysts at Robert W. Baird initiated coverage on shares of Tetraphase Pharmaceuticals in a research note on Monday. They set an “outperform” rating and a $21.00 price target on the stock. Separately, analysts at WBB Securities upgraded shares of Tetraphase Pharmaceuticals from a “speculative buy” rating to a “buy” rating in a research note on Monday, June 2nd. They now have a $16.00 price target on the stock, up previously from $13.50. Finally, analysts at Brean Capital initiated coverage on shares of Tetraphase Pharmaceuticals in a research note on Thursday, April 3rd. They set a “buy” rating and a $23.00 price target on the stock. Eight investment analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and a consensus target price of $18.75.

Tetraphase Pharmaceuticals, Inc, incorporated on July 7, 2006, is a clinical stage biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.